|
ROADMAP
Randomised Olmesartan And Diabetes Microalbuminuria Prevention
Ongoing trial
 |
Author(s) |
Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A |
 |
Title(s) |
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study |
|
Reference(s) |
J Hypertens 2006;24:403–8
|
|
Disease |
Diabetes mellitus |
|
Purpose |
To determine whether olmesartan can prevent or delay the onset of microalbuminuria and whether this translates into cardiovascular and renal protection in patients with type 2 diabetes |
|
Study design |
Randomised, double-blind, placebo-controlled, parallel-group
|
|
Follow-up |
Aim median 5 years |
|
Patients |
Aim 4400 patients, aged 18–75 years with type 2 diabetes and no microalbuminuria, HbA1c ≥ 6.5% or receiving treatment for diabetes and at least one cardiovascular risk factor |
|
Treatment regimen |
Olmesartan medoxomil, 40mg/day, or placebo
|
|
Results |
Not yet available |
|
|
|
